New Advances in Tisotumab Vedotin for Cervical Cancer Treatment

Every year, approximately 4,300 women in Germany receive a diagnosis of cervical cancer, with an average age of onset around 53 years. Tisotumab Vedotin, marketed as Tivdak®, is an innovative therapeutic option specifically designed for adult women dealing with recurrent or metastatic cervical cancer, particularly when the disease has progressed during or after systemic treatment.

This antibody-drug conjugate (ADC), produced by Genmab, combines a fully human IgG1-? antibody (Tisotumab) with a cytotoxic agent known as Monomethyl-Auristatin E (MMAE), linked through a proteolytically cleavable Valine-Citrulline linker. The recommended dosage is 2 mg/kg of body weight, with a maximum of 200 mg for patients weighing over 100 kg, administered every three weeks until disease progression or intolerable toxicity occurs. Detailed guidelines for dosage adjustments and treatment interruptions due to side effects are provided in the prescribing information.

The mechanism of action of Tisotumab Vedotin targets the tissue factor (TF), a transmembrane glycoprotein that is frequently overexpressed in various solid tumors. By binding to TF on tumor cells, the conjugate facilitates internalization and subsequent release of MMAE, which disrupts the microtubule network essential for cell division, leading to cell cycle arrest and apoptosis. In vitro studies have demonstrated its direct cytotoxic effects on TF-expressing cells, as well as on surrounding tumor cells, and have shown capabilities for antibody-dependent cell-mediated cytotoxicity and phagocytosis, contributing to its anti-tumor efficacy.

As a significant advancement in the field of oncology, Tisotumab Vedotin provides hope for improved survival rates among women suffering from advanced cervical cancer. Ongoing clinical trials and studies continue to explore its full potential.